Drug Profile
Research programme: cancer vaccines - Cancure Limited
Alternative Names: GenvaxLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Cancure
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Sep 2023 Preclinical development in Solid-tumours is ongoing in Australia (Parenteral, Injection) (Cancure's website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Solid-tumours in Australia (Parenteral, Injection)